IP77: Bladder Cancer: Basic Research & Pathophysiology II

Monday, May 18, 2026 7:00 AM to 9:00 AM · 2 hr. (America/New_York)
147A
Poster and Podium Sessions
Basic Science ResearchOncology: Bladder

Information

Of Interest To
Researchers

Monday, May 18

IP77-01: Prospective analytical study using real-time Artificial Intelligence (AI) to optimize the diagnostic of bladder tumor detection.

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
Fabien SAINT

IP77-02: Discovery of a Rare Mesenchymal-Like Urothelial Cell Population Resembling the Phenotype of Sarcomatoid  Component of MB49 Bladder Cancer Model

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A

IP77-03: The Impact of Gemcitabine Pretreatment on Docetaxel Penetration in the Bladder

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A

IP77-04: Hydroxyl radical-generating water prevents bladder tumor development through the induction of ferroptosis

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A

IP77-05: RPS4X and RPS4Y1 drive recurrence of non-muscle-invasive bladder cancer by suppressing tumor antigen presentation

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
Meng Ding

IP77-06: Do concomitant auto-immune disorders alter the tumor immune microenvironment and subsequent effectiveness of BCG in non-muscle invasive bladder cancer: a mixed methods study

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A

IP77-07: Spatial Transcriptomics of en bloc Transurethral Resection of Bladder Tumor Specimens Defines an Invasive-Front Gene Expression Signature in Bladder Cancer

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A

IP77-08: Somatic Gene Alterations Associated with Nodal Status and Survival in Urothelial Bladder Cancer

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
Jeanpierre Kanumuambidi · East Carolina university, Brody School of medicine

IP77-09: Immune Oncology Gene and Protein Expression Differences in Urothelial Carcinoma at Primary Site and Lymph Node Metastasis

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A

IP77-10: CD46 as a Theranostic Target in Bladder Cancer: Expression Profiling and Pre-Clinical Validation of [89Zr]Zr-DFO-YS5 PET in Bladder Cancer

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A

IP77-11: Dissecting the tumor microenvironment of advanced urothelial carcinoma pre and post enfortumab vedotin ± pembrolizumab

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A

IP77-12: Using ex vivo culture to evaluate dynamic changes in the bladder and prostate tumor microenvironment following durvalumab treatment.

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A

IP77-13: Molecular mechanism of resistance to enfortumab vedotin (EV) and Nectin-4-modified molecular classification for muscle-invasive bladder cancer (MIBC)

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A

IP77-14: DPP4 Upregulation Drives MMAE Resistance in Bladder Cancer: Therapeutic Potential of Combined Targeting

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A

IP77-15: Inhibiting a2,6-Sialylation Boosts Enfortumab Vedotin Response by Stabilizing Nectin-4 and Enhancing Macropinocytic Uptake in Bladder Cancer

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A

IP77-16: Spatial Immunophenotypes Combined with Neutrophil-to-Lymphocyte Ratio (NLR) Predict Response to Immune Checkpoint Inhibitors (ICIs) and Gemcitabine-Cisplatin Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A

IP77-17: Nanoparticles-mediated mitochondrial iron depletion reversed innate and adoptive immune-resistance to boost bladder cancer immunotherapy

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
Cheng Li

IP77-18: Inactivation of Androgen Receptor (AR) or Estrogen Receptor-ß (ERß) Enhances the Efficacy of Immune Checkpoint Inhibition in Bladder Cancer

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A

IP77-19: Fibrate lipid-lowering drugs enhance the mechanism of immunotherapy for bladder cancer by inhibiting the expression of CD276

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
Cheng Li

IP77-20: Targeting EphA2 reverses immunotherapy resistance in Basal/Squamous bladder cancer via CCL5-mediated T-cell recruitment

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A

IP77-21: Functional Antioxidants and B7-H3 Targeting in Immunocellular Therapy for Bladder Cancer

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
Chien-Hui Lin

IP77-22: Senescent cancer-associated fibroblasts as aged microenvironment develop bladder cancer by CXCL12 secretion

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A

IP77-24: CDK1/HIF-1a Promotes FGFR3-Dependent Bladder Tumor Progression via Glycolytic Signaling

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
Jie Ming

IP77-25: Glucose-Regulated Protein 94 (GRP94) in Bladder Cancer Progression: Is It a “Double-Edged Sword”?

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A

IP77-26: Decoding the Tumor Ecosystem: RNA-seq Profiling Reveals Microbiome–TME Coupling in Bladder Cancer

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A

IP77-27: PRECLINICAL EVALUATION OF FUSOGENIC VACCINIA VIRUS EXPRESSING IMMUNOSTIMULATORY GENES IN SUBCUTANEOUS AND ORTHOTOPIC MOUSE MODELS OF BLADDER CANCER

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A

IP77-29: Comprehensive multi-layered omics analysis of the UBC landscape for precision medicine and its clinical implications: from deciphering distinct molecular heterogeneity to guiding treatment decision-making and developing tailored therapeutic strat

Monday, May 18, 2026 7:00 AM to 9:00 AM
147A

Registered attendees

Petra Popovics
Petra Popovics
Assistant ProfessorEastern Virginia Medical School at Old Dominion University
Yakov Klugman
Yakov Klugman
Medical StudentRoswell Park Comprehensive Cancer Center

Log in

See all the content and easy-to-use features by logging in or registering!